Skip to main content

TransMedics Group, Inc.

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

TMDX$93.79+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Revenue:
Net product revenue$96,100$71,732$184,334$133,057
Service revenue61,27042,573116,57378,098
Total revenue157,370114,305300,907211,155
Cost of revenue:
Cost of net product revenue19,42114,47035,73328,554
Cost of service revenue41,36030,57480,35753,378
Total cost of revenue60,78145,044116,09081,932
Gross profit96,58969,261184,817129,223
Operating expenses:
Research, development and clinical trials15,93413,85833,09425,238
Selling, general and administrative44,08842,89587,71379,056
Total operating expenses60,02256,753120,807104,294
Income from operations36,56712,50864,01024,929
Other income (expense):
Interest expense(3,476)(3,623)(6,937)(7,221)
Interest income and other income (expense), net3,0913,2685,7856,838
Total other expense, net(385)(355)(1,152)(383)
Income before income taxes36,18212,15362,85824,546
(Provision) benefit for income taxes(1,275)41(2,269)(155)
Net income$34,907$12,194$60,589$24,391
Net income per share:
Basic$1.03$0.37$1.79$0.74
Diluted$0.92$0.35$1.62$0.70
Weighted average common shares outstanding:
Basic33,912,66933,119,51433,817,66432,939,852
Diluted40,558,95335,288,30840,238,50134,983,603
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.